Navigation Links
Genedata Expressionist® Established as Data Analysis Platform for Oncological Research

Basel, Switzerland (PRWEB) December 12, 2012

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced its successful contributions to several oncology-related research consortia, including the EU-funded carcinoGENOMICS, Newgeneris, and INCA projects. Genedata Expressionist, the company’s flagship product for molecular profiling applications, was successfully used by these consortia for the analysis and management of complex high-volume, oncology-related data. Additionally, the consortia’s oncology-specific requirements fueled the development of enhanced capabilities in Genedata Expressionist, which are now available to all licensees of the software. A comprehensive and enterprise-level solution, Genedata Expressionist helps to identify and understand molecular biomarkers by easily integrating transcriptomics, genomics, epigenomics, proteomics, and metabolomics data.

In implementing Genedata Expressionist for Genomic Profiling, Genedata domain experts worked closely with several EU research consortia including the carcinoGENOMICS project. carcinoGENOMICS was comprised of 20 research organizations representing the pharmaceutical industry as well as leading academic institutions from across Europe. The consortium developed a series of in vitro tests representative of various modes of carcinogenic action for the major target organs liver, lung, and kidney. This approach enables efficient assessment of a high number of compounds as required under REACH, the European Community Regulations on chemicals and their safe use. Moreover, this testing resulted in best practices required to successfully reduce animal testing while enabling more cost-efficient R&D processes.

“Toxicogenomics research is generating large amounts of complex omics data and researchers are challenged to make sense of these data,” noted Prof. Dr. Jos Kleinjans, scientific director of the Netherlands Toxigenomic Centre, who is the coordinator of the carcinoGENOMICS Project. “Genedata Expressionist helps researchers to effectively meet these challenges, by efficiently analyzing high-throughput molecular profiling data” continued Kleinjans. “Moreover, the Genedata team of scientists provides the necessary expertise to ensure the success of ambitious projects such as ours.”

Researchers use Genedata Expressionist to assess assay reproducibility and predict compound carcinogenicity. Assays are based on the application of omics technologies (i.e. genome-wide transcriptomics and metabolomics) to robust in vitro systems (rat/human). Phenotypic markers for genotoxic and carcinogenic events are assessed to anchor gene expression modulations, metabolic profiles, and mechanistic pathways. Through extensive biostatistics, literature mining, and analysis of molecular-expression datasets, differential genetic pathways are identified, which are capable of predicting mechanisms of chemical carcinogenesis in vivo. Furthermore, Genedata Expressionist is able to integrate transcriptomics and metabolomics data to provide a holistic understanding of systems biology and build an iterative in silico model of chemical carcinogenesis.

Recently, Genedata also contributed its software solutions to a number of innovative EU-funded, oncology-focused projects, including:

  •     NewGeneris – the consortium successfully investigated chemical risks concerning the development of childhood cancer and immune disorders and the role of prenatal exposure to genotoxic chemicals through maternal intake of food during pregnancy.
  •     INCA – the consortium successfully examined the role of chronic viral infections in the development of cancer.

“Genedata is proud to work with some of the leading scientists and research organizations worldwide who are fighting some of the most life-threatening diseases,” said Dr. Othmar Pfannes, CEO of Genedata. “The know-how and experience gathered in such collaborations continues to drive the advancement of Genedata Expressionist – with the enhancements now available to all licensees of the system.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Screener to Present at 10th Annual Ion Channel Retreat
2. First detailed timeline established for brains descent into Alzheimers
3. infirst HEALTHCARE Established to Launch Novel Consumer Medicines
4. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
5. Quality Standards Established for Competition to Identify Best Researchers in the US
6. Rigaku ZSX Primus Application Note: Lubricating Oil Analysis by WDXRF According to ASTM D6443-04
7. Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
8. Sulfur Analysis in Crude Oil and High-Sulfur Fuels by WDXRF According to ASTM D2622-10
9. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
10. Global Medical Image Analysis Software Market Worth $2.4 Billion by 2017
11. Recently Published Economic Analysis Highlights the Financial Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States (US)
Post Your Comments:
(Date:11/30/2015)... Florida , November 30, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, today announced it will be presenting at ... on December 1, 2015 at 2.30 PM PT. Dr. ... and Strategic Advisor will be giving the presentation and ...
(Date:11/30/2015)... 2015  Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage ... will present at two upcoming investor conferences. Aytu is ... virtual conference, to be held December 3, 2015, and ... held December 2 nd & 3 rd , ... streamed live via webcast. Josh Disbrow , ...
(Date:11/30/2015)... RATON, Florida and MAGDEBURG, Germany ... Congress of NeuroRehabilitation (ECNR) in Vienna, Austria ... 3rd European Congress of NeuroRehabilitation (ECNR) in ... 2015. --> NovaVision, a wholly owned subsidiary of ... the European version of its Internet-delivered NovaVision Therapy Suite at ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... integration with MarkLogic, the Enterprise NoSQL database platform provider, creating a seamless ... , Smartlogic’s Content Intelligence capabilities provide a robust set of semantic tools ...
Breaking Biology Technology:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
Breaking Biology News(10 mins):